PT-141 (Bremelanotide)

PT-141 (Bremelanotide) is a melanocortin receptor agonist studied for sexual dysfunction. Works centrally in the brain rather than peripherally like PDE-5 inhibitors. Marketed as Vyleesi for premenopausal women with HSDD.

At a Glance

Summary: Activates melanocortin receptors in the central nervous system to enhance neural pathways involved in sexual desire and arousal. Mechanisms (reported/proposed across domains): Sexual function / libido • Activates MC3R and MC4R receptors in the hypothalamus and limbic system, areas involved in sexual desire, arousal, and motivation. • Works directly on brain pathways to enhance sexual...

Safety Profile

FDA Approved

Research Dosing

Dose: 1–2 mg · Route: Subcutaneous (SC) · Intranasal · Frequency: As needed (max 8×/month) · Duration: Ongoing as needed

Categories

  • FDA Approved
  • Sexual Function
  • Libido Enhancement
  • HSDD Treatment
  • Melanocortin
  • Female Sexual Dysfunction
  • Central Nervous System
  • Desire Enhancement
  • As-Needed Dosing
  • Clinical Data Available

The Leading Community for Trusted Peptide Research & Insights

Research summaries, dosing protocols, and community reports for peptides. Built on clinical data and real-world experiences.